Tananbaum James B.'s Form 4 filing
Theseus Pharmaceuticals, Inc. (THRX) · filed Jul 19, 2023
- Accession no.
- 0001209191-23-042720
- Filed
- Jul 19, 2023, 2:54 PM ET
- Trade date
- Jul 17, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market purchases total $2.08M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Tananbaum James B.CIK 0001581754 | 10% Owner |
| Foresite Capital Fund V, L.P.CIK 0001792204 | 10% Owner |
| Foresite Capital Opportunity Fund V, L.P.CIK 0001792205 | 10% Owner |
| Foresite Capital Management V, LLCCIK 0001792206 | 10% Owner |
| Foresite Capital Opportunity Management V, LLCCIK 0001792207 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 17, 2023 | Common Stock | PPurchaseAcquired | +523,450 | $2.97 | +$1,554,646.5 | 4,108,796 | Indirect | |
| Jul 17, 2023 | Common Stock | PPurchaseAcquired | +176,550 | $2.97 | +$524,353.5 | 1,385,825 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.